HC Wainwright Has Strong Estimate for Evotec FY2026 Earnings

Evotec AG (NASDAQ:EVO) – Investment analysts at HC Wainwright raised their FY2026 earnings estimates for Evotec in a note issued to investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.75) per share for the year, up from their prior forecast of ($0.83). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.13) EPS.

Several other brokerages also recently commented on EVO. Berenberg Bank downgraded Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a report on Wednesday, July 15th. Finally, Weiss Ratings cut Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.50.

Evotec Stock Up 3.0%

Shares of Evotec stock opened at $1.74 on Tuesday. The firm’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $2.47. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. Evotec has a 1-year low of $1.33 and a 1-year high of $3.87.

Institutional Investors Weigh In On Evotec

An institutional investor recently raised its stake in Evotec stock. Optiver Holding B.V. grew its stake in Evotec AG (NASDAQ:EVO) by 598.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 283,576 shares of the company’s stock after acquiring an additional 242,973 shares during the period. Optiver Holding B.V. owned 0.08% of Evotec worth $709,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.